GlassScriptPhysician profile
Alice Lin
NPI 1184769341
$1,204.26
in general payments reported to CMS, 2019-2025
20 companies · $14.30 in 2025
The $14.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $334 · 2021: $379 · 2022: $190 · 2023: $215 · 2024: $72.33 · 2025: $14.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $171.04 | 2021 | |
| Stryker Corporation | $165.27 | 2023 | Clarifix Cryotherapy Device |
| Amgen INC. | $136.04 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2022 | |
| Lilly USA, LLC | $123.71 | 2020-2021 | |
| Allergan, INC. | $70.32 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $52.05 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $48.97 | 2024 | Ycanth |
| Genentech USA, INC. | $42.14 | 2020 | |
| Gilead Sciences, INC. | $41.46 | 2020-2021 | |
| Abbvie INC. | $31.80 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $30.34 | 2020-2021 | |
| Glaxosmithkline, LLC. | $27.12 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.76 | 2022 | |
| Coopersurgical, INC. | $23.48 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $23.36 | 2024 | Cholbam |
| Biohaven Pharmaceuticals, INC. | $20.00 | 2021 | |
| Pfizer INC. | $17.87 | 2023 | |
| Boston Scientific Corporation | $14.30 | 2025 | General - Pain Management |
| Medtronic, INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.